Results support an AD pathogenesis model in which APOE-ε4 and Aβ42 relate to clinical status in early stages of impairment, whereas phosphorylation of tau, synaptic dysfunction, and neurodegeneration drive more severe impairment, possibly leading to quicker clinical decline. This evidence concerns the gene MAPT and Alzheimer disease.